Back to Search
Start Over
Immunotherapeutic strategies for high-risk bladder cancer.
- Source :
-
Seminars in oncology [Semin Oncol] 2007 Apr; Vol. 34 (2), pp. 165-72. - Publication Year :
- 2007
-
Abstract
- Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-grade superficial disease. The nonspecific immune modulation that occurs as a result of BCG therapy is not well understood; however, the success of BCG therapy provides a basis for the exploration of mechanisms related to immune responses and the development of novel immunotherapeutic agents for the treatment of high-risk disease. In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer.
Details
- Language :
- English
- ISSN :
- 0093-7754
- Volume :
- 34
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Seminars in oncology
- Publication Type :
- Academic Journal
- Accession number :
- 17382800
- Full Text :
- https://doi.org/10.1053/j.seminoncol.2006.12.004